JUBLPHARMAPharmaceuticals
Jubilant Pharmova Ltd — Profit & Loss Statement
₹816.45
-1.80%
Jubilant Pharmova Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Unusual Items Excluding Goodwill | 359.50 Cr | -168.90 Cr | -64.50 Cr | -3.22 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 839.40 Cr | 77.10 Cr | -61.00 Cr | 413.94 Cr | — |
| Reconciled Depreciation | 368.60 Cr | 381.90 Cr | 554.00 Cr | 381.70 Cr | — |
| Reconciled Cost Of Revenue | 2.32K Cr | 2.14K Cr | 2.22K Cr | 1.79K Cr | — |
| EBITDA | 1.59K Cr | 824.70 Cr | 750.40 Cr | 1.15K Cr | — |
| EBIT | 1.22K Cr | 442.80 Cr | 196.40 Cr | 768.69 Cr | — |
| Net Interest Income | -240.30 Cr | -272.30 Cr | -178.40 Cr | -143.03 Cr | — |
| Interest Expense | 240.30 Cr | 272.30 Cr | 168.60 Cr | 138.24 Cr | — |
| Normalized Income | 532.80 Cr | 195.33 Cr | -15.85 Cr | 416.05 Cr | — |
| Net Income From Continuing And Discontinued Operation | 839.40 Cr | 77.10 Cr | -61.00 Cr | 413.94 Cr | — |
| Total Expenses | 6.39K Cr | 6.13K Cr | 5.99K Cr | 5.23K Cr | — |
| Diluted Average Shares | 15.88 Cr | 15.86 Cr | 15.91 Cr | 15.92 Cr | — |
| Basic Average Shares | 15.84 Cr | 15.83 Cr | 15.91 Cr | 15.92 Cr | — |
| Diluted EPS | 52.85 | 4.86 | -3.83 | 26.00 | — |
| Basic EPS | 52.99 | 4.87 | -3.83 | 26.00 | — |
| Diluted NI Availto Com Stockholders | 839.40 Cr | 77.10 Cr | -61.00 Cr | 413.94 Cr | — |
| Net Income Common Stockholders | 839.40 Cr | 77.10 Cr | -61.00 Cr | 413.94 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 839.40 Cr | 77.10 Cr | -61.00 Cr | 413.94 Cr | — |
| Minority Interests | 3.10 Cr | 4.40 Cr | 3.90 Cr | 0.92 Cr | — |
| Net Income Including Noncontrolling Interests | 836.30 Cr | 72.70 Cr | -64.90 Cr | 413.02 Cr | — |
| Net Income Continuous Operations | 836.30 Cr | 72.70 Cr | -64.90 Cr | 413.02 Cr | — |
| Tax Provision | 144.30 Cr | 97.80 Cr | 92.70 Cr | 217.43 Cr | — |
| Pretax Income | 980.60 Cr | 170.50 Cr | 27.80 Cr | 630.45 Cr | — |
| Other Non Operating Income Expenses | 56.80 Cr | 68.70 Cr | 11.30 Cr | 8.69 Cr | — |
| Special Income Charges | 359.50 Cr | -168.90 Cr | -59.50 Cr | -3.37 Cr | — |
| Other Special Charges | -475.20 Cr | 168.90 Cr | 59.50 Cr | 3.37 Cr | — |
| Write Off | 24.10 Cr | — | — | — | — |
| Restructuring And Mergern Acquisition | 91.60 Cr | — | — | — | — |
| Net Non Operating Interest Income Expense | -240.30 Cr | -272.30 Cr | -178.40 Cr | -143.03 Cr | — |
| Interest Expense Non Operating | 240.30 Cr | 272.30 Cr | 168.60 Cr | 138.24 Cr | — |
| Operating Income | 805.10 Cr | 518.90 Cr | 229.90 Cr | 824.45 Cr | — |
| Operating Expense | 4.07K Cr | 3.99K Cr | 3.77K Cr | 3.45K Cr | — |
| Other Operating Expenses | 1.48K Cr | 1.45K Cr | 680.00 Cr | 609.71 Cr | — |
| Depreciation And Amortization In Income Statement | 368.60 Cr | 381.90 Cr | 554.00 Cr | 381.70 Cr | — |
| Depreciation Income Statement | 368.60 Cr | 381.90 Cr | 316.10 Cr | 292.16 Cr | — |
| Gross Profit | 4.88K Cr | 4.50K Cr | 4.00K Cr | 4.27K Cr | — |
| Cost Of Revenue | 2.32K Cr | 2.14K Cr | 2.22K Cr | 1.79K Cr | — |
| Total Revenue | 7.19K Cr | 6.64K Cr | 6.22K Cr | 6.06K Cr | — |
| Operating Revenue | 7.19K Cr | 6.64K Cr | 6.22K Cr | 6.06K Cr | — |
| Tax Effect Of Unusual Items | 52.90 Cr | -50.67 Cr | -19.35 Cr | -1.11 Cr | — |
| Tax Rate For Calcs | 0.15 | 0.30 | 0.30 | 0.34 | — |
| Normalized EBITDA | 1.23K Cr | 993.60 Cr | 814.90 Cr | 1.15K Cr | — |
| Total Unusual Items | 359.50 Cr | -168.90 Cr | -64.50 Cr | -3.22 Cr | — |
| Interest Income | — | 26.10 Cr | 9.80 Cr | 2.45 Cr | 8.10 Cr |
| Rent Expense Supplemental | — | 4.90 Cr | 7.80 Cr | 4.50 Cr | 4.91 Cr |
| Total Other Finance Cost | — | 15.90 Cr | 19.60 Cr | 7.25 Cr | 10.74 Cr |
| Interest Income Non Operating | — | 26.10 Cr | 9.80 Cr | 2.45 Cr | 8.10 Cr |
| Amortization | — | 52.10 Cr | 237.90 Cr | 89.55 Cr | 88.50 Cr |
| Selling General And Administration | — | 440.60 Cr | 384.70 Cr | 455.51 Cr | 409.41 Cr |
| Selling And Marketing Expense | — | 214.30 Cr | 161.60 Cr | 209.71 Cr | 177.15 Cr |
| General And Administrative Expense | — | 226.30 Cr | 223.10 Cr | 245.80 Cr | 232.26 Cr |
| Rent And Landing Fees | — | 4.90 Cr | 7.80 Cr | 4.50 Cr | 4.91 Cr |
| Net Income Discontinuous Operations | — | — | — | 0.00 | 261.75 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Jubilant Pharmova Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.